AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Sobre

A Curaleaf Holdings (OTC: CURLF) é uma das maiores operadoras de cannabis multi-estado nos Estados Unidos, operando cultivo, processamento e operações de varejo de dispensárias em numerosos estados com significativa presença internacional na Europa por meio de sua aquisição da EMMAC Life Sciences. A empresa construiu uma plataforma verticalmente integrada com um portfólio de marcas próprias, incluindo Select, Grassroots e Find, gerando entre as maiores receitas de qualquer empresa de cannabis dos EUA. Como investimento, a Curaleaf oferece exposição direta ao mercado de cannabis dos EUA com escala operacional e diversificação geográfica, embora sua listagem OTC, desafios contínuos de lucratividade em toda a indústria e a cronologia incerta para reforma federal permaneçam considerações importantes para os investidores.

Ações de Cannabis

A Curaleaf é uma ação de cannabis líder representando um dos maiores operadores de maconha que tocam plantas nos Estados Unidos, com um portfólio de dispensários de múltiplos estados e cultivo que a posiciona para se beneficiar significativamente de qualquer legalização federal ou reclassificação de cannabis.

Key Financials CURA

Preço $3.31
Variação (1D) +2.16%
Variação (30D) -7.54%
Variação (60D) +21.25%
Variação (90D) -24.43%
Variação (180D) +171.31%
Variação (1Y) +57.62%
P/E Ratio -12.26
EPS (TTM) $-0.27
Faixa de 52 Semanas $0.99 — $6.98
MA de 50 Dias $3.68
Volume 355.4K

Data updated Feb 15 · Source: Twelve Data

4.2
2 reviews
Performance
4
Management Quality
3.8
Valuation
3.4
Fundamentals
3.2
Risk Profile
2.8
Claude Opus 4.6
AI Review
4.2/5

Curaleaf Holdings is the largest multi-state cannabis operator in the U.S. by revenue, with operations spanning cultivation, processing, and retail across numerous states and international markets. The company's scale provides meaningful competitive advantages in procurement, branding, and regulatory navigation.

The bull case centers on Curaleaf's market leadership position and potential federal rescheduling or legalization catalysts, evidenced by the 171% gain over six months as sentiment improved. Its extensive retail footprint and brand portfolio (Select, Grassroots) create durable competitive moats in a fragmented industry.

However, the bear case is significant. The negative P/E ratio of -12.26 and EPS of -$0.27 reflect ongoing profitability challenges common across cannabis MSOs. The stock trades well below its 52-week high of $6.98, and the 24% decline over 90 days suggests fading momentum as rescheduling timelines remain uncertain. Heavy debt loads and 280E tax burdens continue to pressure cash flows.

Curaleaf remains a top-tier cannabis play for investors with high risk tolerance, but profitability must materialize to justify current valuations. Regulatory catalysts remain the key swing factor.

Performance
4
Management Quality
3.8
Valuation
3.4
Fundamentals
3.2
Risk Profile
2.8
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.2/5

Curaleaf Holdings maintains its status as a top-tier U.S. Multi-State Operator (MSO), distinguished by its massive geographic footprint and strategic expansion into the European market. For investors, the primary thesis rests on Curaleaf's scale advantage and its ability to capitalize on potential regulatory shifts, such as federal rescheduling. However, the company's financials reflect the broader challenges of the cannabis industry; with a trailing EPS of -$0.27 and a negative P/E ratio, profitability remains hindered by tax burdens and capital-intensive growth. The stock currently trades at $3.24, which is below its 50-day moving average of $3.68, indicating recent bearish momentum despite trading significantly above its 52-week low of $0.99. While Curaleaf represents one of the more stable vehicles for exposure to the cannabis sector, it remains a speculative investment requiring patience for regulatory clarity and improved cash flow generation.

Feb 11, 2026
Curaleaf Holdings Screenshot

Added: Feb 10, 2026

curaleaf.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

Como Fazer Backtest de uma Estratégia de Trading: Métodos, Armadilhas e O Que os Resultados Realmente Significam

Como Fazer Backtest de uma Estratégia de Trading: Métodos, Armadilhas e O Que os Resultados Realmente Significam

Todo trader tem uma estratégia que parece ótima em sua cabeça. Backtesting é como você descobre se ela realmente funciona. Aqui está como testar estratégias adequadamente, quais métricas importam e por que a maioria dos resultados de backtest é boa demais para ser verdade.